Abstract Denosumab (Prolia®; Pralia®) is a human monoclonal antibody targeting the key
bone resorption mediator RANKL. The drug is administered via subcutaneous injection once …

Osteoporosis, a syndrome characterized by thin bones and fractures, has become more
prevalent in both women and men. Established therapies for treating this disorder consist …

The final analysis of this 2-year, randomized, crossover study showed that postmenopausal
women with osteoporosis were more adherent, compliant, and persistent with subcutaneous …

In this study, 250 women with osteoporosis were randomized to 12 months with
subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly …

Denosumab (Prolia®) is a human recombinant monoclonal antibody that is approved for the
treatment of postmenopausal osteoporosis in women at high or increased risk of fracture in …

This retrospective database study assessed 2-year persistence with bisphosphonates or
denosumab in a large German cohort of women with a first-time prescription for osteoporosis …

Objectives Medication nonadherence is common for osteoporosis, but its consequences
have not been well described. This study aimed to quantify the clinical and economic …

Objective: To assess the cost-effectiveness as well as adherence and patient preference for
denosumab compared with oral bisphosphonates for the treatment of osteoporosis. Data …

Background: Denosumab has recently been shown to be well tolerated, to increase bone
mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral …

The purposes of the study were to review available published literature on magnitude of non-
adherence with osteoporosis regimens and to determine the association between frequency …